Page last updated: 2024-11-07

alpha-conotoxin imi

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID133011
CHEMBL ID500076
MeSH IDM0232195

Synonyms (7)

Synonym
glycyl-cysteinyl-cysteinyl-seryl-asparginyl-prolyl-arginyl-cysteinyl-alanyl-tryptophyl-arginyl-cysteinamide
l-cysteinamide, glycyl-l-cysteinyl-l-cysteinyl-l-seryl-l-alpha-aspartyl-l-prolyl-l-arginyl-l-cysteinyl-l-alanyl-l-tryptophyl-l-arginyl-, cyclic (2-8),(3-12)-bis(disulfide)
alpha-ctx-imi
gly-cys-cys-ser-asp-pro-arg-cys-ala-trp-arg-cys-nh2
alpha-conotoxin imi ,
CHEMBL500076
DTXSID10166085

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Furthermore, the biological activities of intracranially applied alpha-CTx ImI and alpha-CTx ImII are similar over the same dosage range, and are consistent with alpha7 nAChR inhibition."( Alpha-conotoxins ImI and ImII. Similar alpha 7 nicotinic receptor antagonists act at different sites.
Ellison, M; McIntosh, JM; Olivera, BM, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID367851Antagonist activity at nAChR in nicotine-stimulated bovine adrenal chromaffin cells assessed as inhibition of adrenaline release preincubated for 5 mins before nicotine challenge by RP-HPLC2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Structure and activity of (2,8)-dicarba-(3,12)-cystino alpha-ImI, an alpha-conotoxin containing a nonreducible cystine analogue.
AID367850Antagonist activity at nAChR in nicotine-stimulated bovine adrenal chromaffin cells assessed as inhibition of noradrenaline release preincubated for 5 mins before nicotine challenge by RP-HPLC2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Structure and activity of (2,8)-dicarba-(3,12)-cystino alpha-ImI, an alpha-conotoxin containing a nonreducible cystine analogue.
AID367852Activation of rat alpha7 nAChR expressed in Xenopus laevis oocytes at 2.5 uM2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Structure and activity of (2,8)-dicarba-(3,12)-cystino alpha-ImI, an alpha-conotoxin containing a nonreducible cystine analogue.
AID367853Antagonist activity at rat alpha7 nAChR expressed in Xenopus laevis oocytes assessed as inhibition of acetylcholine-evoked ion current at 2.5 uM treated 3 mins prior to acetylcholine challenge measured after 2 to 4 days by two-electrode voltage clamp meth2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Structure and activity of (2,8)-dicarba-(3,12)-cystino alpha-ImI, an alpha-conotoxin containing a nonreducible cystine analogue.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's20 (43.48)18.2507
2000's15 (32.61)29.6817
2010's11 (23.91)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.49 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (97.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]